Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (May 2023)
23 slides from Beta Drugs's investor presentation, May 8, 2023
Slide 1: Investor Presentation FY'23
Investor Presentation FY ‘ 23
Slide 2: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 3: Making Complex Oncology products Accessible to Indian cancer patients
Making Complex Oncology products Accessible to Indian cancer patients Building healthier world By providing affordable & With focus on R&D quality Oncology medicines With 2 formulations & 1 API state-of- 64 products 22 new products launched in last 4 the-art manufacturing facilities 112 SKUs years 1
Slide 4: Formulations and API Plant
Formulations and API Plant BETA DRUGS LTD. ADLEY FORMULATIONS PVT LTD. ADLEY LAB LTD. : API Plant Address: Address: Address: KHARUNI-LODHI MAJRA VILLAGE KOTLA,P.O. D-27 FOCAL POINT ROAD,VILL.NANDPUR,BADD BAROTIWALA,SOLAN DERABASSI SAS I-174101 DIST-SOLAN (HP) (HP)-174103 Nagar PUNJAB Facility for ma
Slide 5: Affordable Quality Medicine
Affordable Quality Medicine Leading brands
Slide 6: Focus on R&D
Focus on R&D New product development are pivotal to our growth No of the brands launched Sales of FFTLs 1311 7 7 8 4 NDDS 5 700 3 4 New Products 152 FY'21 FY'22 FY'23 FY'20 FY'21 FY'22 FY'23 FY'24 plan FFTL: First Few To Launch Value in Lakhs FY 2019-20 FY 2020-21 FY 2021-22 FY 2022-23 DASATINIB ENZ
Slide 7: Focus on R&D
Focus on R&D 3 new brands launched in FY 22-23: Carfimib , Adcilib & Adleap 160mg Strong product pipeline Working on NDDS (New Drug Delivery System). Recently got DCGI approval for Enzalutamide 160mg. Working on FFTLs to be launched in FY’24
Slide 8: Key Competitive Strengths
Key Competitive Strengths Market leadership Among top 10 players in cytotoxic market Infrastructure & quality Financial performance Strong financial performance Robust track record of compliance with well-defined growth and Quality levers Management Team Backward integration BDL is among the few com
Slide 9: Healthy Growth Across All Segments in FY'23 (Y-O-Y)
Healthy Growth Across All Segments in FY’23 (Y-O-Y) Domestic Own brand International CDMO 24 % revenue growth 31 % revenue growth 64 % revenue growth 13 % revenue growth
Slide 10: Domestic Own Brand Business
Domestic Own Brand Business Finished formulation sales 68 55 • Penetration in tier 2 & 3 cities • New product launches 33 • Field force expansion • Deeper penetration in private, corporate & government hospitals FY'21 FY'22 FY'23
Slide 11: International Business
International Business 3 major international accreditations International business 28 21.3 18.6 These accreditations lead to Geographical expansion in • South Africa & Africa- Namibia, Botswana, Zimbabwe, Zambia, Uganda, Ivory Coast, • North Africa- Morocco, Algeria, • Middle East -Syria, Iraq, Jord
Slide 12: Strong In-House API Development
Strong In-House API Development • The company is aggressively working to file its first CEP (Europe). In lieu of that, we have established a world-class microbial Lab with the latest equipment API Business 18 • Captive expansion- Added 1 new line to focus on EU GMP. • 5 GLR (3250 Litres capacity) &
Slide 13: Strong In-House API Development
Strong In-House API Development AFATINIB ELTROMBOPAG OIAMINE CABOZANTINIB CARFILZOMIB
Slide 14: Our CDMO Partners
Our CDMO Partners ✓ Partnership with 50+ companies ✓ 20+ top pharma companies are associated with us since last 5 years Trusted ✓ Capacity of lyophilized products has increased. It helped to reduce lead Partners time for order execution 109 96 We value our 58 CDMO partners Sustained growth FY'21 FY'
Slide 15: Future Roadmap
FUTURE ROADMAP 450 Cr. 227 Cr. FY’26 FY’23 FY’22 FY’21 The company aims to establish its presence and expand in Indian & international markets
Slide 16: Road Map for Domestic Branded Market
Road Map for Domestic Branded Market Strengthen product basket Increase customer base Market penetration 25 % increase in customer base through: • Increasing presence in tier 2 & tier 3 cities • New corporate & private hospital entries. • Entry into major Govt. institutes • Strengthening Hemato & Ur
Slide 17: Foraying into Cosmetic Dermatology
Foraying into Cosmetic Dermatology Total Market :~ 13700 Cr. Aesthetic Medical Market size: 3600Cr Market size: 10100Cr Fast growing market: 15% Y-O-Y growth 20% growth of the aesthetic market & 12 % growth of the medical Dermatology market First to launch product Product Acceptance Future Plan Sign
Slide 18: Geographical Expansion
Geographical Expansion LatAm ASIA No. of targeted countries: 15 No. of targeted countries: 6 Total dossiers submission plan Total dossiers submission in next 2 years: 86 plan in next 2 years: 134 MIDDLE EAST & AFRICA CIS No. of targeted countries: 11 No. of targeted countries: 4 Total dossiers submi
Slide 19: API Expansion Plan
API Expansion Plan • Foraying into the European market • In FY’24 planning to file 5 CEPs • Focus on export in the nonregulated, semi- regulated, and regulated market Geographical expansion Increase • Plant audit by major pharmaceutical presence in companies for Indian business domestic • Increasing
Slide 20: Healthy Growth in Revenue & Profit
Healthy Growth in Revenue & Profit PERFORMANCE FY’23 Consolidated FY’21 FY’22 FY’23 3 Yrs (Rs Cr) (Rs Cr) (Rs Cr) CAGR Total revenue 116.12 183.84 227.11 25.1% EBITDA 25.24 43.51 53.88 28.8% EBITDA % 21.7% 23.6% 23.7% PAT 11.72 24.83 30.72 37.9% PAT % 10.10% 13.51% 13.53%
Slide 21: Balance Sheet
Balance Sheet FY’21 FY’22 FY’23 (Rs Cr) (Rs Cr) (Rs Cr) Share capital 9.61 9.61 9.61 Reserves 59 82.73 113.27 Borrowing (Long term & 14.7 16.58 16.04 short term) Other liabilities 34.22 48.93 59.5 Total liabilities 117.5 157.85 198.42 Fixed asset 42.78 54.96 62.76 (Net of depreciation) Non current i
Slide 22: Financial Performance
Financial Performance --------------------------------------------------------------------------- 60.0 EBITDA 53.9 % Gross margin 50.0 43.5 42.8% 40.0 30.0 25.2 39.0% 20.0 37.8% 10.0 0.0 FY'21 FY'22 FY'23 FY'21 FY'22 FY'23 -----------------------------------------------------------------------------
Slide 23: Thank You
THANK YOU Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India) Website: www.betadrugslimited.com Email: info@betadrugslimited.com